Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00054873 · ClinicalTrials.gov registry record · Phase 2

Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer

A Phase 2 study, sponsored by Chiron Corporation.

Completed
Registry status
Phase 2
Development phase

NCT00054873: Completed Phase 2 study, sponsored by Chiron Corporation.

NCT00054873 is a Phase 2 study that has completed, run by Chiron Corporation. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00054873, a Phase 2 study, has completed, sponsored by Chiron Corporation.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

The purpose of this study is to evaluate the efficacy and safety of tezacitabine when given alone or in combination with 5-fluorouracil (5-FU) to subjects who have advanced esophageal or gastric adenocarcinoma.

Interventions

  • DRUG 5-fluorouracil
  • DRUG tezacitabine

Trial Details

FieldValue
Start Date 2003-11
Est. Completion 2004-12
Phase Phase 2
Chiron Corporation

9 total trials

What the finished NCT00054873 record still lists

NCT00054873 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 2 interventions - of which 5-fluorouracil is the first listed.

NCT00054873 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00054873 about?

NCT00054873 is a clinical study titled "Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer". The purpose of this study is to evaluate the efficacy and safety of tezacitabine when given alone or in combination with 5-fluorouracil (5-FU) to subjects who have advanced esophageal or gastric adenocarcinoma.

What is the current status of trial NCT00054873?

This trial is currently completed. It is a Phase 2 study. The study started on 2003-11. Estimated completion is 2004-12.

What interventions are being tested in trial NCT00054873?

The interventions under investigation include: 5-fluorouracil (DRUG), tezacitabine (DRUG).

Who is sponsoring clinical trial NCT00054873?

This trial is sponsored by Chiron Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00054873, the US trial registry maintained by the National Library of Medicine. NCT00054873 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.